Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well hydroxychloroquine works in treating patients with
previously treated prostate cancer. Autophagy destroys proteins and other substances in cells
and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks
autophagy, may slow the growth of and possibly kill prostate cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey